Viridian Therapeutics, Inc. VRDN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$104.9M-20.7% | -$120.36M-51.0% | -$34.6M+54.9% | -$100.74M-55.0% | -$86.91M-79.0% | ||
| $121K+3.4% | $120K-2.4% | $110K-15.4% | $113K-20.4% | $117K-19.3% | ||
| $13.39M+31.0% | $11.99M+33.6% | $11.25M+29.0% | $10.84M-7.8% | $10.22M-19.5% | ||
| $4.63M+162% | —— | $1.55M-47.2% | $4.63M+957% | $1.77M+266% | ||
| -$23.69M-48.9% | $21.32M+97.5% | —— | —— | -$15.91M-1,679% | ||
| $2.33M+919% | —— | -$3.37M-186% | -$5.19M— | -$285K-106% | ||
| -$169K-2,917% | -$70.16M-11,216% | $70M+68,527% | -$6K+94.1% | $6K— | ||
| -$119.65M-29.1% | -$23.75M+67.6% | -$84.61M-25.0% | -$75.37M-63.6% | -$92.65M-105% | ||
| $23K-73.3% | $240K+111% | $127K-56.7% | $42K-59.6% | $86K— | ||
| $91.32M+28.2% | $438.19M+141% | $14.09M-93.8% | $55.76M-5.9% | $71.24M-68.4% | ||
| $168.6M-1.6% | $99.01M-16.8% | $140.29M-2.6% | $131.52M+8.4% | $171.39M+108% | ||
| $77.26M-22.8% | -$339.42M-439% | $126.08M+249% | $75.72M— | $100.06M+170% | ||
| $0-100% | $48.24M+43.4% | $11.84M— | $0— | $4.94M-97.3% | ||
| —— | $119.5K— | $119.5K— | $119.5K— | $119.5K— | ||
| $6.36M-31.0% | $405.91M+1,043% | $10.86M-95.6% | $764K+607% | $9.21M-94.8% | ||
| -$36.04M-317% | $42.74M+142% | $52.32M-43.5% | $1.11M-93.1% | $16.62M+249% | ||
| $1.12M+150% | $788K+74.0% | $457K0.0% | $457K-0.2% | $448K-0.9% | ||
| $1.86M-20.0% | $1.75M-45.3% | $1.13M-66.4% | $1.55M-64.8% | $2.32M-50.2% | ||
| $7.53M— | —— | —— | —— | $0— | ||
| —— | $437.75K— | $437.75K— | $437.75K— | $437.75K— | ||
| $2.33M+919% | —— | -$3.37M-186% | -$5.19M— | -$285K-106% | ||
| -$169K-2,917% | —— | —— | —— | $6K— | ||
| $2.34M+2,176% | $2.26M+3,727% | —— | —— | $103K— | ||
| $168.6M-1.6% | $99.01M-16.8% | $140.29M-2.6% | $131.52M+8.4% | $171.39M+108% | ||
| —— | $1.25M— | $1.25M— | $1.25M— | $1.25M— | ||
| —— | $119.5K— | $119.5K— | $119.5K— | $119.5K— | ||
| $0-100% | —— | —— | —— | $207K-98.0% | ||
| —— | $13.75M— | $13.75M— | $13.75M— | $13.75M— | ||
| $0-100% | —— | $559K+76.3% | —— | $561K+57.6% | ||
| $0-100% | —— | —— | —— | $1.62M— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$119.68M-29.0% | -$23.99M+67.3% | -$84.74M-24.6% | -$75.42M-63.4% | -$92.74M-105% | ||
| -$119.68M-29.0% | -$23.99M+67.3% | -$84.74M-24.6% | -$75.42M-63.4% | -$92.74M-105% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viridian Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.